Posted by Michael Wonder on 27 May 2020
Bristol Myers Squibb receives European Commission approval for Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease
27 May 2020 - Zeposia is the only approved sphingosine-1-phosphate receptor modulator for RRMS patients with active disease.
Bristol Myers Squibb today announced that the European Commission has approved Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease as defined by clinical or imaging features.
The approval is based on data from the SUNBEAM and RADIANCE Part B clinical trials showing that, as compared to Avonex (interferon beta-1a), Zeposia delivered powerful efficacy as measured by annualised relapse rate, as well as on the number and size of brain lesions.
